SAN JOSE, Calif., Nov. 29, 2016 /PRNewswire/ -- MIODx announced today the addition of Jill Hagenkord MD to the company's Board of Directors. Dr. Hagenkord recently joined Color Genomics as its Chief Medical Officer (CMO). Prior to Color Genomics, Dr. Hagenkord served as CMO for 23andMe, senior vice president of medical strategy of Invitae, and CMO at Complete Genomics. She is a board-certified molecular genetic pathologist with extensive experience in medical affairs, laboratory operations, and corporate strategy. "Dr. Hagenkord joining the MIODx board of directors couldn't come at a better time," stated Sean Givens, COO of MIODx, "We're in the middle of attaining our CLIA and CAP accreditation, so having the insight of an industry veteran is indispensable. Dr. Hagenkord's experience and guidance will help us avoid many of the pitfalls along the way."
Next quarter MIODx is launching a pilot project with collaborators that utilizes NGS to profile T and B-cell repertoires. The platform utilizes proprietary bioinformatics and biostatistics to identify patterns of immune response. MIODx also plans to launch the VerifyDx prostate cancer test that utilizes captured tumor and normal cells to provide better insight into the tumor's aggressiveness in Q2-17. "The addition of Dr. Hagenkord provides support to fuel discovery, implementation, and distribution of state-of-the art molecular diagnostics worldwide," stated M. Allen Northrup PhD FRSC, CEO of MIODx. "Dr Hagenkord's background in the genetic testing business will be instrumental in MIODx's success in genomics-based diagnostics going forward," Dr. Northrup added. About MIODx MIODx is a privately held company pioneering the discovery of early detection and prognostic cancer biomarkers through the company's proprietary platforms. The company's VerifyDx™ platform utilizes a highly sensitive, multiplex PCR assay and advanced bioinformatics to interrogate multiple DNA and RNA pathways that are implicated in highly metastatic cancer. In addition to the VerifyDx™ platform, MIODx utilizes high throughput immune sequencing to generate information on T and B cell diversity that can be applied to monitoring a patient's response to immunotherapy, discover new targets for drug companies, or to profile an individual's adaptive immune system over time.